Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
Trial details
- Registry ID
- NCT06652633
- Drugs studied
- GLPG CAR T-cell therapy
TrialRedline tracks 11 clinical trials sponsored by Lakefront Biotherapeutics NV: 4 Phase 3, 7 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell TherapiesNCT06652633 | GLPG CAR T-cell therapy | Recruiting | 2039-07Estimated |
| Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseaseNCT02914561 | Filgotinib | Completed | 2022-11-11Actual |
| A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in RemissionNCT05479058 | Filgotinib | Terminated | 2023-10-09Actual |
| Filgotinib in Long-Term Extension Study of Adults With Crohn's DiseaseNCT02914600 | Filgotinib | Terminated | 2023-08-01Actual |
Names as written in the registry records.
NCT05695950 · Lakefront Biotherapeutics NV
Before: Active not recruiting. After: Completed.
NCT05856448 · Lakefront Biotherapeutics NV
Before: Active not recruiting. After: Completed.
NCT05695950 · Lakefront Biotherapeutics NV
Before: Estimated. After: Actual.
Before: Oct 2025. After: 13 Oct 2025.
NCT05856448 · Lakefront Biotherapeutics NV
Before: Estimated. After: Actual.
Before: Oct 2025. After: 8 Oct 2025.